(Reuters) -Eli Lilly hit $1 trillion in market value on Friday, making it the first drugmaker to enter the exclusive club dominated by tech giants and underscoring its rise as a weight-loss powerhouse.
Here are some reactions to Lilly joining the trillion dollar club:
EVAN SEIGERMAN, ANALYST AT BMO CAPITAL MARKETS
"The current valuation points to investor confidence in the longer-term durability of the company's metabolic health franchise. It also suggests that investors prefer Lilly over Novo in the obesity arms race. Taking a step back, we're also seeing money rotate into the sector as investors may be worried about an AI bubble."
HANK SMITH, DIRECTOR & HEAD OF INVESTMENT STRATEGY AT LILLY SHAREHOLDER HAVERFORD TRUST
"Investors have historically liked secure earnings growth and (Eli Lilly) is the only large cap pharma that has that kind of earnings profile."
(Reporting by Siddhi Mahatole and Shashwat Chauhan in Bengaluru; Editing by Leroy Leo)
LATEST POSTS
- 1
An Ideal Getaway - Spots for Solo Travel - 2Germany paves the way for tighter EU asylum rules
- 3Make your choice for the PS5 game that you love playing with companions!
- 4Hypothermia claims newborn in Gaza and more babies are at risk, doctor says
- 5Israel reports second missile fire from Yemen since start of Iran war
- Apollo's impatient old-timers are rooting for NASA's return to the moon with Artemis II launch
- Katz, IDF: We assassinated IRGC intelligence chief Majid Khademi
- Interstellar comet 3I/ATLAS reveals weird wobbling jets in rare sun-facing tail
- Artemis II astronauts channel Apollo 8 with a striking Earthset photo
- NASA is sending astronauts back to the moon. Can you see the Artemis 4 landing sites from Earth?
- The Most Astonishing Arising Advances to Watch
- Taylor Swift's 'The End of an Era' docuseries: Everything you need to know, plus how to watch for less
- 'Heated Rivalry's Ilya Rozanov is now a queer icon in Russia
- Excelling at Discussion: Genuine Examples of overcoming adversity
